Immune response after influenza vaccination in children with cancer

Authors:

Abstract
Purpose To assess the immune response to inactivated trivalent split influenza vaccine in children with cancer. Procedures Forty‐four children with various types of malignancies received two doses of influenza vaccine 2–4 weeks apart. Hemagglutinin‐inhibition (HI) antibody titers were determined in paired sera obtained just before the first vaccination and 4 weeks after the second vaccination. Results Influenza vaccine was administered to all children without any serious adverse effects. Protective titer rates (proportion of patients achieving antibody titers ≥40 among those with pre‐vaccination titers P = 0.006) and 25% versus 83% for H3N2 (P = 0.019). For influenza B, patients with low IgG showed a lower response rate than those with high IgG (29% vs. 61%, P = 0.040). Multivariate analysis revealed that factors significantly associated with a lower immune response were low IgG (P < 0.001) and administration of chemotherapy (P = 0.003) for H1N1, administration of chemotherapy (P = 0.008) for H3N2, and low white blood cell (WBC) count (P = 0.030) and low IgG (P = 0.030) for influenza B. Conclusions Influenza vaccination given to children with cancer was safe and induced immune reaction comparable to healthy children, although patients on chemotherapy and/or with chemotherapy‐related conditions had a limited ability to produce a sufficient immune response.

This publication has 34 references indexed in Scilit: